- Home
- TARS vs BHE Comparison
TARS vs BHE Comparison
Compare TARS & BHE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TARS | BHE |
|---|---|---|
| Founded | 2016 | 1979 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Electrical Products |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 2.9B |
| IPO Year | 2020 | 1996 |
Fundamental Metrics
Financial Performance| Metric | TARS | BHE |
|---|---|---|
| Price | $69.88 | $72.82 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 2 |
| Target Price | ★ $99.80 | $86.00 |
| AVG Volume (30 Days) | ★ 589.3K | 350.8K |
| Earning Date | 11-03-2026 | 10-28-2026 |
| Dividend Yield | N/A | ★ 0.93% |
| EPS Growth | ★ 48.21 | N/A |
| EPS | N/A | ★ 0.91 |
| Revenue | $451,360,000.00 | ★ $2,659,108,000.00 |
| Revenue This Year | $61.17 | $12.94 |
| Revenue Next Year | $26.47 | $7.05 |
| P/E Ratio | ★ N/A | $80.44 |
| Revenue Growth | ★ 146.71 | 0.11 |
| 52 Week Low | $53.89 | $41.69 |
| 52 Week High | $91.53 | $100.41 |
Technical Indicators
Market Signals| Indicator | TARS | BHE |
|---|---|---|
| Relative Strength Index (RSI) | 39.09 | 33.50 |
| Support Level | $69.47 | $71.33 |
| Resistance Level | $73.45 | $87.58 |
| Average True Range (ATR) | 2.85 | 2.36 |
| MACD | -0.68 | -1.49 |
| Stochastic Oscillator | 0.91 | 11.50 |
Price Performance
Historical ComparisonAbout TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.
About BHE Benchmark Electronics Inc.
Benchmark Electronics Inc is engaged in product designing, engineering services, technology solutions, and manufacturing services (electronic manufacturing services (EMS) and precision technology services). It serves various industries, including aerospace & defense (A&D), medical technologies, complex industrials, semiconductor capital equipment, next-generation telecommunications, and high-end computing. Its geographical segments are the Americas, Asia, and Europe, of which key revenue is derived from the Americas.